Silverstone P H, Done C, Sharp T
MRC Unit, Radcliffe Infirmary, Oxford, UK.
Psychopharmacology (Berl). 1992;109(1-2):235-8. doi: 10.1007/BF02245506.
In this study we have examined whether the alpha 2-adrenoceptor agonist clonidine and the calcium channel antagonist nifedipine firstly inhibit the naloxone-precipitated withdrawal syndrome in morphine-dependent rats and secondly reduce central noradrenaline release during withdrawal. We demonstrate that both clonidine (0.1 mg/kg) and nifedipine (10 mg/kg) attenuate the naloxone-precipitated withdrawal syndrome. Using in vivo microdialysis, we demonstrate that following naloxone the release of noradrenaline, as measured by perfusates from hippocampus, increases 300% in morphine-dependent rats. However, whilst pretreatment with clonidine inhibited this increased noradrenaline release, nifedipine did not. These findings suggest that whilst the action of clonidine in attenuating the morphine withdrawal syndrome may be mediated by decreasing central noradrenaline release, this is not the mechanism by which nifedipine acts.
在本研究中,我们考察了α2-肾上腺素能受体激动剂可乐定和钙通道拮抗剂硝苯地平,其一是否能抑制吗啡依赖大鼠中纳洛酮诱发的戒断综合征,其二是否能在戒断期间减少中枢去甲肾上腺素的释放。我们证明,可乐定(0.1毫克/千克)和硝苯地平(10毫克/千克)均能减轻纳洛酮诱发的戒断综合征。使用体内微透析技术,我们证明,在吗啡依赖大鼠中,注射纳洛酮后,海马灌流液中测得的去甲肾上腺素释放量增加了300%。然而,虽然可乐定预处理可抑制这种去甲肾上腺素释放增加,但硝苯地平却不能。这些发现表明,虽然可乐定减轻吗啡戒断综合征的作用可能是通过减少中枢去甲肾上腺素释放来介导的,但这不是硝苯地平发挥作用的机制。